Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tissue factor pathway inhibitor-2
(
TFPI-2
) is a Kunitz-type serine proteinase inhibitor with inhibitory activity toward activated factor XI, plasma kallikrein, plasmin, certain matrix metalloproteinases, and the tissue factor-activated factor VII complex. In addition,
TFPI-2
has other functions such as promoting cell migration and inducing apoptosis. In the present study, we investigated if
TFPI-2
induced apoptosis in cultured U937-derived macrophages and the possible signal pathways that involved in the apoptotic process. Apoptotic DNA fragment detection and
caspase-3
,9 activity measurements indicated that rTFPI-2 promoted U937-derived macrophage apoptosis. Hoechst 33342 assay and flow cytometry further showed that rTFPI-2 induced apoptosis in cultured macrophages in a dose-dependent manner. Because death receptors of the TNF family such as Fas are the best-understood death pathways that recruit Fas-associated death domain (FADD) and procaspase-8 to the receptor in macrophages, we investigated the expression of Fas and its ligand (FasL) and downstream signal caspase-8 by Western blot analysis. The results indicated that the process of apoptosis triggered by rTFPI-2 was, at least in part, actively conducted by U937-derived macrophages possibly through Fas/FasL signal pathway. In brief, rTFPI-2 may have the potential usefulness in inducing macrophages apoptosis, which suggest
TFPI-2
might have antiatherogenic effects.
...
PMID:Recombinant TFPI-2 enhances macrophage apoptosis through upregulation of Fas/FasL. 2119 24
Tissue factor pathway inhibitor-2
(
TFPI-2
) has been identified as a tumor suppressor gene in several types of cancers, but its role in gallbladder carcinoma (GBC) is yet to be determined. In the present study,
TFPI-2
expression in GBC tissues was examined, and its inhibitory activities against GBC growth were evaluated in vitro and in vivo after adenovirus-mediated gene transfer of
TFPI-2
(Ad5-
TFPI-2
) was constructed to restore the expression of
TFPI-2
in GBC cell lines (GBC-SD, SGC-996, NOZ) and xenograft tumors. Immunohistochemical staining showed that
TFPI-2
was significantly downregulated in GBC tissue specimens. Ad5-
TFPI-2
could significantly inhibit GBC growth both in vitro and in vivo. Apoptosis analysis and western blotting assay demonstrated that Ad5-
TFPI-2
could induce the apoptosis of both GBC cell lines and tissues by promoting the activities of cytochrome c, Bax,
caspase-3
and -9 and suppressing Bcl-2 activity. These data indicated that
TFPI-2
acts as a tumor suppressor in GBC, and may have a potential role in gene therapy for GBC.
...
PMID:Adenovirus-mediated gene transfer of tissue factor pathway inhibitor-2 inhibits gallbladder carcinoma growth in vitro and in vivo. 2232 Aug 35